+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn

+ Translate
+ Recently Requested

Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant



Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant



New England Journal of Medicine 340(14): 1063-1070, April 8



Background The intraocular ganciclovir implant is effective for local treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome (AIDS), but it does not treat or prevent other systemic manifestations of cytomegalovirus infection. Methods Three hundred seventy-seven patients with AIDS and unilateral cytomegalovirus retinitis were randomly assigned to one of three treatments: a ganciclovir implant plus oral ganciclovir (4.5 g daily), a ganciclovir implant plus oral placebo, or intravenous ganciclovir alone. The primary outcome measure was the development of new cytomegalovirus disease, either contralateral retinitis or biopsy-proved extraocular disease. Results The incidence of new cytomegalovirus disease at six months was 44.3 percent in the group assigned to the ganciclovir implant plus placebo, as compared with 24.3 percent in the group assigned to the ganciclovir implant plus oral ganciclovir (P=0.002) and 19.6 percent in the group assigned to intravenous ganciclovir alone (P<0.001). As compared with placebo, oral ganciclovir reduced the overall risk of new cytomegalovirus disease by 37.6 percent over the one-year period of the study (P=0.02). However, in the subgroup of 103 patients who took protease inhibitors, the rates of new cytomegalovirus disease were low and of similar magnitude, regardless of treatment assignment. Progression of retinitis in the eye that initially received an implant was delayed by the addition of oral ganciclovir, as compared with placebo (P=0.03). Treatment with oral or intravenous ganciclovir reduced the risk of Kaposi's sarcoma by 75 percent (P=0.008) and 93 percent (P<0.001), respectively, as compared with placebo. Conclusions In patients with AIDS and cytomegalovirus retinitis, oral ganciclovir in conjunction with a ganciclovir implant reduces the incidence of new cytomegalovirus disease and delays progression of the retinitis. Treatment with oral or intravenous ganciclovir also reduces the risk of Kaposi's sarcoma.

(PDF emailed within 1 workday: $29.90)

Accession: 011096439

Download citation: RISBibTeXText



Related references

Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. New England Journal of Medicine 340(14): 1063-1070, 1999

The ganciclovir implant plus oral ganciclovir versus parenteral cidofovir for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: The Ganciclovir Cidofovir Cytomegalovirus Retinitis Trial. American Journal of Ophthalmology 131(4): 457-467, April, 2001

Ganciclovir implant and oral ganciclovir vs cidofovir for cytomegalovirus retinitis in patients with AIDS The ganciclovir cidofovir cytomegalovirus retinitis trial. IOVS 42(4): S567, March 15, 2001

Complications of ganciclovir implant surgery in patients with cytomegalovirus retinitis: the Ganciclovir Cidofovir Cytomegalovirus Retinitis Trial. Retina 24(1): 41-50, 2004

Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group. New England Journal of Medicine 333(10): 615-620, 1995

Clinical outcomes in patients with cytomegalovirus retinitis treated with ganciclovir implant. American Journal of Ophthalmology 153(4): 728-33, 733.E1-2, 2012

Occult fellow eye CMV retinitis in patients treated with ganciclovir implants and oral ganciclovir. Investigative Ophthalmology & Visual Science 38(4 PART 1-2): S741, 1997

Incremental cost-effectiveness analysis of intravenous ganciclovir versus oral ganciclovir in the maintenance treatment of newly diagnosed cytomegalovirus retinitis in patients with AIDS. Pharmacoeconomics 16(1): 71-84, 1999

Cytomegalovirus (CMV) resistance in patients with CMV retinitis and AIDS treated with oral or intravenous ganciclovir. Journal of Infectious Diseases 179(6): 1352-1355, 1999

Genotypic analysis of cytomegalovirus retinitis poorly responsive to intravenous ganciclovir but responsive to the ganciclovir implant. American Journal of Ophthalmology 135(1): 20-25, 2002

Genotypic analysis of cytomegalovirus retinitis poorly responsive to intravenous ganciclovir but responsive to the ganciclovir implant. American Journal of Ophthalmology 135(1): 20-25, January, 2003

Effect of potent antiretroviral therapy on recurrent cytomegalovirus retinitis treated with the ganciclovir implant. American Journal of Ophthalmology 127(3): 283-287, 1999

Intravenous versus oral ganciclovir: European/Australian comparative study of efficacy and safety in the prevention of cytomegalovirus retinitis recurrence in patients with AIDS. The Oral Ganciclovir European and Australian Cooperative Study Group. Aids 9(5): 471-477, 1995

Endophthalmitis after ganciclovir implant in patients with AIDS and cytomegalovirus retinitis. American Journal of Ophthalmology 136(4): 649-654, 2003

Monitoring plasma levels of ganciclovir in AIDS patients receiving oral ganciclovir as maintenance therapy for CMV retinitis. Clinical Microbiology and Infection 6(3): 117-120, 2000